APA

Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., Vandemeulebroucke E., Van de Velde U., Crenier L., De Block C., Candon S., Waldmann H., Ziegler A. G., Chatenoud L. & Pipeleers D. (20100423). Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. : Diabetologia.

Chicago

Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler A G, Chatenoud L and Pipeleers D. 20100423. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. : Diabetologia.

Harvard

Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., Vandemeulebroucke E., Van de Velde U., Crenier L., De Block C., Candon S., Waldmann H., Ziegler A. G., Chatenoud L. and Pipeleers D. (20100423). Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. : Diabetologia.

MLA

Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler A G, Chatenoud L and Pipeleers D. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. : Diabetologia. 20100423.